Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Targeting hepatitis B virus covalently closed circular DNA in vitro and in vivo

EF 2019-20

Résumé
"Despite the availability of an effective vaccine, still over 257 million people worldwide are chronically infected with the hepatitis B virus (HBV). The HBV targets specifically liver cells and can cause a persistent (or chronic) infection that can lead to severe liver scarring and liver cancer. HBV related liver complications accounts for over 880,000 deaths annually. HBV's ability to cause chronic infection is due, in part, to its highly stable DNA genome (called cccDNA), which enters and remains in the nucleus of infected liver cells. Once in the nucleus, the cccDNA acts as a ""mini-factory"" to produces new virus particles. There is no cure for chronic HBV infection, and current first line anti-HBV treatments block the virus at later steps, but do not affect the formation or destruction of cccDNA. To achieve a cure, the cccDNA needs to be targeted for elimination. We aim to (1) design a drug to stop the production of new cccDNA particles; (2) characterize the drugs effect on cccDNA production; (3) study the anti-HBV drug in mouse models. To complete these aims we have designed a drug to bind specifically to a region on the cccDNA that is responsible for the production of new cccDNA particles. The drug will be tested in HBV infected liver cells for drug toxicity, efficacy, and markers of HBV replication. To study the drug's ability to target HBV infected liver cells, the drug will be labelled with a marker that can be visualized. Similarly, these marked drugs will be injected into mice models to confirm HBV targeting in the liver using technologies that allow visualization of animal organs. This research will provide insight into new cccDNA targeting approaches which will inform development of an HBV cure to improve health outcomes of chronic HBV infected patients."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428780
Name
D'souza Simmone
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting hepatitis B virus covalently closed circular DNA in vitro and in vivo
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antiviral Therapeutic Development; Dna G-Quadruplex; Drug Discovery; G-Quadruplex Binding Proteins; Hepatitis B Virus; Hepatitis B Virus Covalently Closed Circular Dna; Protein Therapeutics; Rational Drug Design; Targeting Covalently Closed Circular Dna; Transcription Inhibition
Abstract
"Despite the availability of an effective vaccine, still over 257 million people worldwide are chronically infected with the hepatitis B virus (HBV). The HBV targets specifically liver cells and can cause a persistent (or chronic) infection that can lead to severe liver scarring and liver cancer. HBV related liver complications accounts for over 880,000 deaths annually. HBV's ability to cause chronic infection is due, in part, to its highly stable DNA genome (called cccDNA), which enters and remains in the nucleus of infected liver cells. Once in the nucleus, the cccDNA acts as a ""mini-factory"" to produces new virus particles. There is no cure for chronic HBV infection, and current first line anti-HBV treatments block the virus at later steps, but do not affect the formation or destruction of cccDNA. To achieve a cure, the cccDNA needs to be targeted for elimination. We aim to (1) design a drug to stop the production of new cccDNA particles; (2) characterize the drugs effect on cccDNA production; (3) study the anti-HBV drug in mouse models. To complete these aims we have designed a drug to bind specifically to a region on the cccDNA that is responsible for the production of new cccDNA particles. The drug will be tested in HBV infected liver cells for drug toxicity, efficacy, and markers of HBV replication. To study the drug's ability to target HBV infected liver cells, the drug will be labelled with a marker that can be visualized. Similarly, these marked drugs will be injected into mice models to confirm HBV targeting in the liver using technologies that allow visualization of animal organs. This research will provide insight into new cccDNA targeting approaches which will inform development of an HBV cure to improve health outcomes of chronic HBV infected patients."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
D'souza, Simmone
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~